OCA
ASND icon

Octagon Capital Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Octagon Capital Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-83,500
Closed -$8.62M – 36
2022
Q3 		$8.62M Buy
+83,500
New +$7.92M 1.49% 17

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Octagon Capital Advisors's ASND Position: Q4 2022 in Review

Octagon Capital Advisors sold out of Ascendis Pharma A/S (ASND) in Q4 2022, closing a stake of 83,500 shares — an estimated $8.62M sold.

Octagon Capital Advisors first reported a position in ASND in Q3 2022 and held it in 1 quarter. The position peaked at $8.62M in Q3 2022. 187 funds tracked by Wall St. Rank hold ASND as of Q4 2022.

  • Octagon Capital Advisors reported no remaining Ascendis Pharma A/S position as of Q4 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 83,500 Ascendis Pharma A/S shares in Q4 2022, an estimated $8.62M.
  • Octagon Capital Advisors first reported a position in Ascendis Pharma A/S in Q3 2022 and held it in 1 quarter.
  • Octagon Capital Advisors's Ascendis Pharma A/S position peaked at $8.62M in Q3 2022.
  • 187 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2022.

Based on Octagon Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.